Clinical trials sponsored by GlaxoSmithKline

Phase breakdown

Conditions studied

Recruiting trials led by GlaxoSmithKline

• A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
  NCT07221188 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 66 locations
• A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
  NCT07712393 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 91 locations
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 114 locations
• A Study of Depemokimab in Participants of 6 to 11 Years of Age
  NCT07671001 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · 3 locations
• A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
  NCT07456033 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 17 locations
• A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
  NCT07358546 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 3 locations
• A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
  NCT06920043 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 30 locations
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
  NCT06576271 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 28 locations
• A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
  NCT06990880 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
  NCT07277270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
  NCT07099898 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 132 locations
• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
  NCT07371468 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 19 locations
• A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
  NCT06567782 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
  NCT05757102 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 67 locations
• A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
  NCT06433921 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
  NCT07502560 · Phase: Phase 4 · Ages: 76 Years and older · Sex: All (male and female) · 8 locations
• A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
  NCT07213609 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
  NCT06885034 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 170 locations
• Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
  NCT06979323 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 50 locations
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 15 locations
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 159 locations
• Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
  NCT06405230 · Phase: Phase 1, Phase 2 · Ages: 30 Years and older · Sex: All (male and female) · 1 location
• First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
  NCT07332455 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 11 locations
• Open-label Extension Study in Participants With Early Alzheimer's Disease
  NCT07105709 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 33 locations
• Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
  NCT05855200 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 266 locations
• Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
  NCT06527872 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 121 locations

Common questions

How many trials is GlaxoSmithKline recruiting for?

GlaxoSmithKline is the lead sponsor of 28 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.